(19)
(11) EP 1 888 578 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
03.04.2013 Bulletin 2013/14

(45) Mention of the grant of the patent:
30.11.2011 Bulletin 2011/48

(21) Application number: 06753710.0

(22) Date of filing: 18.05.2006
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 35/00(2006.01)
 A61K 31/4188(2006.01)
A61P 29/00(2006.01)
(86) International application number:
PCT/EP2006/004725
(87) International publication number:
WO 2006/122806 (23.11.2006 Gazette 2006/47)

(54)

2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR

2-METHYL-2-[4-(3-METHYL-2-OXO-8-CHINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] CHINOLINYL)-PHENYL]PROPIONITRIL ALS LIPIDKINASE-HEMMER

2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLÉIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLÉINYL)-PHENYL]PROPIONITRILE EN TANT QU'INHIBITEUR DE KINASE LIPIDIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

(30) Priority: 20.05.2005 GB 0510390

(43) Date of publication of application:
20.02.2008 Bulletin 2008/08

(60) Divisional application:
10175369.7 / 2292617
10175375.4 / 2270008

(73) Proprietor: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • GARCIA-ECHEVERRIA, Carlos
    CH-4052 Basel (CH)
  • STAUFFER, Frédéric
    CH-4153 Reinach (CH)
  • FURET, Pascal
    F-68800 Thann (FR)

(74) Representative: Graff, Alan 
Novartis AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
WO-A1-2005/054237
WO-A2-03/097641
 WO-A1-2005/054238
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).